Plain-English translation of NCT05820841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a medication called Acalabrutinib to a standard chemotherapy combination (called ) helps older adults with diffuse large B-cell lymphoma live longer without their cancer coming back. Half of participants will receive the standard chemotherapy alone, and half will receive the same chemotherapy plus the new medication. The goal is to see if adding this treatment improves how long people stay in remission.
Standard chemotherapy for this type of blood cancer works, but doctors want to know if adding this medication might help people stay healthier for longer. Older adults often need gentler treatment options, and this trial is designed to see if this new medication can safely improve their outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either standard chemotherapy alone or chemotherapy plus the new medication over several months. You will receive 6 cycles of chemotherapy with 2 additional infusions of a targeted antibody drug, and if in the experimental group, you will also take the new medication by mouth daily throughout your treatment. You'll have regular visits to your clinic for infusions, blood tests, and check-ups to monitor how you're responding and manage any side effects.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Germany